首页> 外文期刊>Cell Communication and Signaling >The let-7 family of microRNAs suppresses immune evasion in head and neck squamous cell carcinoma by promoting PD-L1 degradation
【24h】

The let-7 family of microRNAs suppresses immune evasion in head and neck squamous cell carcinoma by promoting PD-L1 degradation

机译:Let-7 MicroRNAS系列通过促进PD-L1降解抑制头部和颈部鳞状细胞癌中的免疫湿法

获取原文
       

摘要

Accumulation of immunosuppressive protein programmed death-ligand 1 (PD-L1) has been documented in several cancers and contributes to the evasion of the host immune system. However, cancer cell-intrinsic signaling-dependent control of PD-L1 expression remains to be elucidated. Herein, we aimed to identify the let-7 family of microRNAs as candidates that up-regulate tumor cell PD-L1 expression and mediates immune evasion of head and neck squamous cell carcinoma (HNSCC). The expression of let-7 family and PD-L1 was quantified in HNSCC tissues and adjacent normal tissues. PD-L1 degradation was evaluated in HNSCC cells in response to elevated expressions of let-7a or let-7b. The regulation of let-7 family on PD-L1 degradation through a mechanism involving T-cell factor-4 (TCF-4) control of β-catenin/STT3 pathway was evaluated. Immune recognition of HNSCC in vivo was examined in subcutaneous tumor-bearing C3H mice in the presence of let-7a/b and/or CTLA-4 antibody. The let-7 family were significantly down-regulated in the context of HNSCC, sharing a negative correlation with PD-L1 expression. Glycosylated PD-L1 was detected in HNSCC cells, which was reduced by let-7a/b over-expression. TCF-4, the target of let-7a/b, activated the β-catenin/STT3 pathway and promoted PD-L1 degradation. In vivo analysis demonstrated that let-7a/b over-expression potentiated anticancer immunotherapy by CTLA-4 blockade. Taken together, our findings highlight targeting let-7 family as a potential strategy to enhance immune checkpoint therapy for HNSCC.
机译:免疫抑制蛋白程序的积累已在几种癌症中记载了死亡 - 配体1(PD-L1),有助于宿主免疫系统的逃避。然而,癌症细胞内在信号依赖性对PD-L1表达的依赖性控制仍有待阐明。在此,我们的旨在鉴定Let-7微大RORNA系MicroRNA系,以调节肿瘤细胞PD-L1表达和介导头颈鳞状细胞癌(HNSCC)的免疫湿法。在HNSCC组织和相邻的正常组织中定量了Let-7系列和PD-L1的表达。响应于Let-7a或Let-7b的升高表达,在HNSCC细胞中评估PD-L1降解。评价通过涉及β-Catenin / STT3途径的T细胞因子-4(TCF-4)控制的机制对PD-L1降解的Let-7系列的调节。在Let-7A / B和/或CTLA-4抗体存在下,在皮下肿瘤C3H小鼠中检测体内HNSCC的免疫识别。在HNSCC的背景下,Let-7系列显着下调,与PD-L1表达共享负相关。在HNSCC细胞中检测到糖基化的PD-L1,其通过Let-7a / b过度表达还原。 TCF-4,Let-7A / B的靶标,活化β-连环蛋白/ STT3途径并促进PD-L1降解。体内分析证明,通过CTLA-4阻断,Let-7A / B过度表达具有增强的抗癌免疫疗法。我们的研究结果突出了靶向让-7系列作为增强HNSCC免疫检查点治疗的潜在策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号